Cirsiliol Alleviates Experimental Inflammatory Bowel Disease via Restoration of Intestinal Barrier Integrity and Inhibition of NF-κB and MAPK Pathways
Abstract
Inflammatory
bowel
disease
(IBD)
is
a
chronic
gastrointestinal
disorder
characterized
by
intestinal
inflammation
and
barrier
dysfunction.
This
study
investigated
the
therapeutic
potential
of
Cirsiliol,
natural
flavonoid,
in
DNBS-induced
murine
colitis
model..Mice
were
randomly
divided
into
control,
model,
Cirsiliol
treatment
groups
(10
mg/kg
30
mg/kg).
Disease
activity
was
assessed
through
body
weight,
colon
length,
index
(DAI).
Molecular
mechanisms
evaluated
using
immunohistochemistry,
Western
blot,
biochemical
assays.
significantly
ameliorated
symptoms,
reducing
weight
loss
DAI
scores
while
improving
length.
Mechanistically,
suppressed
pro-inflammatory
cytokines
(TNF-α,
IL-6,
IL-1β),
enhanced
antioxidant
defenses
(increased
GSH,
decreased
MDA),
restored
tight
junction
protein
expression
(Claudin-1,
Occludin,
E-cadherin).
Furthermore,
it
modulated
apoptosis-related
proteins
(reduced
Bax,
Caspase-3;
increased
Bcl-2)
promoted
epithelial
migration.
Research Square (Research Square), Год журнала: 2025, Номер unknown
Опубликована: Апрель 8, 2025
Язык: Английский